Tracing Alzheimer’s Through Blood and Synapses: A New Frontier in Neuroscience

As a neuroscientist in training, I am constantly struck by the complexity of the brain and the challenges of studying it. Few conditions illustrate this more clearly than Alzheimer’s disease (AD), which continues to test both our scientific understanding and the limits of clinical practice. For decades, we have relied on positron emission tomography (PET) and cerebrospinal fluid (CSF) assays to measure amyloid and tau pathology. These approaches have been invaluable, yet they remain expensive, invasive, and impractical for large-scale or routine use.

Recently, however, three landmark studies have profoundly reshaped my perspective. Together, they show that peripheral biomarkers in blood and CSF can capture the disease continuum, spanning amyloid deposition, tau phosphorylation, neuroaxonal degeneration, astroglial activation, and even synaptic resilience. For me, these findings are not simply experimental results; they represent a decisive shift towards a more accessible and biologically precise neuroscience.

The first study, conducted in a large Swedish cohort, demonstrated that plasma p-tau181, p-tau217, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) are strong predictors of future dementia, with follow-up extending over sixteen years. What impressed me most was the negative predictive value above 90%, meaning that low concentrations of these markers reliably reflect preserved neural integrity across multiple domains: axonal, astrocytic, and tau-related microtubule stability. Such findings highlight how resilience in the ageing brain can now be quantified long before clinical symptoms appear.

Building on this, the second study dissected tau biology in plasma with unprecedented detail, using targeted mass spectrometry across two independent cohorts. The results revealed a temporal cascade in which specific tau species became abnormal at different points in the Alzheimer’s continuum. From these observations, the researchers developed a plasma-based staging model that proved highly reproducible and closely aligned with amyloid and tau PET, cortical atrophy, and cognitive decline. For me, this demonstrates that the sequential phosphorylation of tau, once confined to post-mortem tissue, can now be monitored dynamically in living humans through a simple blood test.

The third study extended this framework to address one of the most important questions in AD research: why do some individuals with heavy pathological burden remain cognitively intact, while others decline rapidly? Large-scale CSF proteomics from nearly 3,400 participants revealed synaptic proteins as the strongest correlates of cognitive impairment, independent of amyloid and tau. The YWHAG:NPTX2 ratio emerged as particularly powerful, explaining up to 27% of the variance in cognition beyond classical markers such as CSF pTau181:Aβ42. It also predicted progression over 15 years and signalled decline decades before onset in autosomal dominant AD mutation carriers. Mechanistically, this imbalance between a 14-3-3 signalling protein and a regulator of synaptic scaling reflects a breakdown of synaptic homeostasis — providing a molecular explanation for cognitive vulnerability.

When viewed together, these findings converge into a coherent framework. Alzheimer’s can no longer be seen simply as the accumulation of amyloid plaques and tau tangles, but as a network disorder in which pathology, degeneration, and resilience interact. Blood and CSF biomarkers now allow us to trace these processes across molecular, cellular, and systems levels, offering a multidimensional picture of disease progression. For me, this shift is transformative: it takes neuroscience beyond symptom-based definitions and towards a biological atlas of disease that bridges molecular pathology with clinical outcomes.

I see these discoveries as both an intellectual challenge and an opportunity. The challenge lies in mastering the diverse methods, from fluid biomarkers to imaging and proteomics, that are reshaping the field! The opportunity lies in contributing to a future in which individuals can be identified in preclinical phases, interventions can be delivered before irreversible neuronal loss, and resilience itself becomes a measurable dimension of brain health. I believe we are now witnessing the dawn of preventive neuroscience: an era in which dementia is no longer defined only at the bedside or in the post-mortem brain, but by biological signatures that can be captured in blood and CSF, tracing Alzheimer’s across the blood–brain barrier and revealing both vulnerability and strength.

References

Oh H, Chen TW, Karch CM, Fagan AM, Bateman RJ, Buckley RF, et al. A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer’s disease. Nat Med. 2025;31:1592–603. Available from: https://doi.org/10.1038/s41591-025-03565-2

Palmqvist S, Tideman P, Cullen NC, Janelidze S, Ström P, Mattsson-Carlgren N, et al. Plasma biomarkers and risk of dementia: a population-based cohort study. Nat Med. 2025;31:1967–77. Available from: https://doi.org/10.1038/s41591-025-03605-x

Barthelemy NR, Ashton NJ, Leuzy A, Cullen NC, Janelidze S, Elman J, et al. Longitudinal plasma tau species across the Alzheimer’s disease continuum. Nat Aging. 2025;5:655–69. Available from: https://doi.org/10.1038/s43587-025-00951-w